Joshua A. Linscott

Dr. Joshua A. Linscott


Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2024 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
JLJoshua A. Linscott
Joshua A. Linscott
HMHiroko Miyagi
Hiroko Miyagi
PMPrithvi B. Murthy
Prithvi B. Murthy
SYSijie Yao
Sijie Yao
GGG. Daniel Grass
G. Daniel Grass
RLRoger Li
Roger Li

25 January 2024 in European Urology
Verified
Journal Article
Closed access
JLJoshua A. Linscott
Joshua A. Linscott
JMJoshua J. Meeks
Joshua J. Meeks
LDLars Dyrskjøt
Lars Dyrskjøt
Roger LiRoger Li
Roger Li

1 March 2021 in Urologic Oncology: Seminars and Original Investigations
Verified
Journal Article
Closed access
WDWilliam C. Daly
William C. Daly
PHPaul K.J. Han
Paul K.J. Han
MHMatthew Hayn
Matthew Hayn
SRStephen T. Ryan
Stephen T. Ryan
MHMoritz H. Hansen
Moritz H. Hansen
JSJesse D. Sammon
Jesse D. Sammon

1 June 2021 in Journal of Urology
Verified
Journal Article
Closed access
WDWilliam C. Daly
William C. Daly
JLJoshua A. Linscott
Joshua A. Linscott
PHPaul K. J. Han
Paul K. J. Han
MHMatthew H. Hayn
Matthew H. Hayn
MHMoritz H. Hansen
Moritz H. Hansen
JSJesse D. Sammon
Jesse D. Sammon
Purpose:Medicaid expansion under the Affordable Care Act (ACA) occurred almost concurrently with 2012 USPSTF recommendations against PSA screening. Here the relative influence on PSA screening rate...


13 March 2022 in medRxiv
Verified
Preprint
Open access
PDF file
MPMeghana S. Pagadala
Meghana S. Pagadala
JLJoshua A. Linscott
Joshua A. Linscott
JTJames Talwar
James Talwar
TSTyler Seibert
Tyler Seibert
BRBrent Rose
Brent Rose
SRStephen T. Ryan
Stephen T. Ryan
Prostate cancer (PrCa) is one of the most genetically driven solid cancers with heritability estimates as high as 57%. African American men are at an increased risk of PrCa; however, current risk prediction models are based on European ancestry groups and may not be broadly applicable. In this study, we define an African ancestry group of 4,533 individuals to develop an African ancestry-specific PrCa polygenic risk score (PRState). We identified risk loci on chromosomes 3, 8, and 11 in the African ancestry group GWAS and constructed a polygenic risk score (PRS) from 10 African ancestry-specific PrCa risk SNPs, achieving an AUC of 0.61 [0.60-0.63] and 0.65 [0.64-0.67], when combined with age and family history. Performance dropped significantly when using ancestry-mismatched PRS models but remained comparable when using trans-ancestry models. Importantly, we validated the PRState score in the Million Veteran Program, demonstrating improved prediction of PrCa and metastatic PrCa in African American individuals. This study underscores the need for inclusion of individuals of African ancestry in gene variant discovery to optimize PRS.